Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936013 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL14068812 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL4936008 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL4932634 | 0.99 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL4932643 | 0.99 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL4932640 | 0.99 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL5220077 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL5220068 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL5220060 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL5221229 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | HUMPHREY JOHN MICHAEL | 2008-09-11 | — | — | US | disclosed |
| US-7381741-B2 | In which the amino is substituted by arylmethyl- or heteroarylmethyl- group, e.g., 2-Methoxybenzyl)-(2-phenylpyrrolidin-3-yl)-amine and 5-{[2-(3-Chloro-phenyl)-pyrrolidin-3-ylamino]-methyl}-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphalen-2-one; neurokinin 1 (Substance P) inhititors | PFIZER INC (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1753718-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20050288358-A1 | 3-amino-2-phenylpyrrolidine derivatives | PFIZER INC. | 2005-12-29 | — | — | US | disclosed |
| WO-2005115976-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PBK, KCND3, KCND2 | SMN1; SMN2 2785/4885NPC1 544/4885RAB9A 3111/4885 |
| US-20050288358-A1 | 3-amino-2-phenylpyrrolidine derivatives | PBK, KCND3, KCND2 | SMN1; SMN2 2785/4885NPC1 544/4885RAB9A 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.